IDH1 and acute myeloid leukemia: It is approved as monotherapy for treatment of R/R IDH1-mutated AML and as frontline therapy for patients with newly diagnosed IDH1-mutated AML who are ineligible for intensive chemotherapy based on early phase trials showing durable remissions in these patient populations (4, 5).